


Medicines and Suicide

A tool to support effective conversations with patients, carers and colleagues



- 1. Are the patient's symptoms improving?
- 2. Are medicines causing intolerable problems?
- 3. Is treatment evidence-informed and optimised?
- 4. Is the patient prescribed medicines with significant toxicity in overdose?
- 5. Is the patient and/or carer appropriately involved in decision-making about medicines?
- 6. Is the patient at risk of misusing alcohol, illicit substances, "over-thecounter" medicines or prescribed medicines, including opiates?
- 7. Does the patient have access to a stockpile of medicines?
- 8. Does the patient have an agreed safety plan?
- 9. Who else do I need to inform?
- 10. When will the patient next be reviewed?

General Advice to Healthcare Professionals about medicines and suicide or self-harm

General Advice to Healthcare Professionals about medicines and suicide or self-harm	
Antidepressants	Antidepressant medication for major depressive disorder is associated with a substantial decrease in suicide risk.
	A reduction in prescription of SSRI antidepressants to treat depression in youths in the US,
	Canada and the Netherlands was associated with an increased suicide rate.
	There remains controversy about the proportional impact of, and potential for, suicide-
	promoting effects of antidepressants in children, adolescents and young adults under the
	age of 25 years. Analyses suggest a small number of young patients may develop new
	suicidal ideation or self-harm with SSRI treatment, overall SSRI treatment of major
	depression substantially decreases suicide rates and suicide attempts.
	When present, the risk appears to relate to the initial (up to 6) weeks of treatment
	supporting antidepressant guideline recommendations for close monitoring for worsening
	of depressive symptoms and emergence of suicidal thought during the initial phase of
	treatment.
Sedatives/	There is evidence that sedatives/hypnotics produce depressant and/or disinhibitory effects
hypnotics	in a small proportion of people and may be best avoided in suicidal patients.
Treating	A mood stabiliser is often needed in addition to an antipsychotic in the long term
schizophrenia	management of schizoaffective disorder. The long-term effectiveness of lithium in reducing
and psychosis	death by suicide and attempted suicide is well established
Clozapine	One study found that treatment with the antipsychotic medicine clozapine is significantly
	more effective than olanzapine in preventing suicide attempts in patients with
	schizophrenia and schizoaffective disorder at high risk of suicide. In 2003 the US Food and
	Drug Administration (FDA) approved clozapine for the reduction of suicide risk on
	schizophrenia.
Lithium	The long-term effectiveness of lithium in reducing death by suicide and attempted suicide in
	patients with bipolar disorder and schizoaffective disorder is well established. Withdrawal
	of lithium treatment may be associated with an increased rate of suicide. Patients who
	attempt suicide while on lithium may require a change in medication due to its high
	lethality when taken in overdose.
Valproate	Reports on the relative efficacy of valproate-containing medicines in preventing suicide
	attempts or death by suicide compared with lithium are mixed. These medicines should not
	be used in women of child-bearing potential unless they are the only option and highly
	effective contraception is being used.
Treating	Current guidelines reflect an evidence base suggesting no medicines regimen improves the
borderline	overall symptoms of borderline personality disorder and the use of medicines is not
personality	recommended by NICE. Short-term sedative medication may be appropriate for a crisis
disorder	which might involve an escalation of self-harm thoughts and acts. Medication may be
	appropriate for any co-morbid conditions such as depression or anxiety.
Treating ADHD	On large study showed that treatment of ADHD with medication decreased suicidal
	behaviour. Stimulant medication should be used with caution of there has been any
	substance misuse in the last year. It is advisable to use longer-acting medicines as these
	have less potential to be misused.
	Follow guidance when prescribing stimulant medication and monitoring the physical health
If a seal of the	of people taking it.
If people might	Provide people with alcohol/substance/medication dependence or misuse who are
be misusing	experiencing suicidal ideation, or have self-harmed, with immediate attention, and support
alcohol, illicit	access to specific treatments for the chemical dependence and/or specific treatments for
substances or	any comorbid disorders. This may include treatments that target symptoms such as anxiety,
prescribed	agitation, insomnia and panic attacks and/or referral to specialist substance misuse services
medicines	where these are commissioned. Additional support for safety may include patient-held
	naloxone where such services exist. Use the " <u>Talk to Frank</u> " website to inform conversations about harms and risks
	Consider the RCGP advice on dependence forming medicines (<u>DFMs</u>)

For further information refer to BMJ Best Practice guidance on suicide <u>https://bestpractice.bmj.com/topics/en-gb/1016</u>